Cytokinetics investor relations material

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company’s lead drug candidate is tirasemtiv, a fast skeletal muscle activator that is the subject of FORTITUDE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis. It is also developing omecamtiv mecarbil an engineered cardiac myosin activator that is in Phase 2 development for the treatment of systolic heart failure.